Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 7/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 7/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.74 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299748 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL11710419 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL13014950 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL14619144 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL13589886 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL11487059 | 0.83 | OPRD1 (0.71) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL18408052 | 0.82 | OPRM1 (0.70) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL2909939 | 0.82 | OPRM1 (0.70) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL1206232 | 0.82 | OPRM1 (0.70) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL12894697 | 0.81 | OPRM1 (0.68) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1091759-B1 | COMPOSITION FOR THE INDUCTION OF APOPTOSIS IN TARGET CELLS | UNIV DUNDEE (GB) | 2012-10-24 | — | — | EP | claimed |
| US-20040019060-A1 | Sigma receptor ligands and their medical uses | SPRUCE BARBARA ANN (GB) | 2004-01-29 | — | — | US | claimed |
| JP-2003528916-A | — | — | 2003-09-30 | — | — | JP | claimed |
| EP-1267875-A1 | SIGMA RECEPTOR LIGANDS AND THEIR MEDICAL USES | Spruce, Barbara (GB) | 2003-01-02 | — | — | EP | claimed |
| WO-2001074359-A1 | SIGMA RECEPTOR LIGANDS AND THEIR MEDICAL USES | SPRUCE BARBARA (GB) | 2001-10-11 | — | — | WO | claimed |
| WO-1995006468-A1 | METHOD FOR TREATING MIGRAINE HEADACHES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-03-09 | — | — | WO | claimed |
| EP-4313039-B1 | BENZOMORPHAN DERIVATE FOR USE IN THERAPY | MOLECULAR RES PHARMACT S R L (IT) | 2025-09-03 | — | — | EP | disclosed |
| US-20240197699-A1 | BENZOMORPHAN DERIVATE FOR USE IN THERAPY | MOLECULAR RESEARCH PHARMACT S.R.L. (IT) | 2024-06-20 | — | — | US | disclosed |
| EP-4313039-A1 | BENZOMORPHAN DERIVATE FOR USE IN THERAPY | Molecular Research Pharmact S.r.l. (IT) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022208375-A1 | BENZOMORPHAN DERIVATE FOR USE IN THERAPY | MOLECULAR RESEARCH PHARMACT S.R.L. (IT) | 2022-10-06 | — | — | WO | disclosed |
| US-20220009919-A1 | PREPARATION OF N-MONOFLUOROALKYL COMPOUNDS | GE HEALTHCARE LTD (GB) | 2022-01-13 | — | — | US | disclosed |
| EP-2513099-B1 | PREPARATION OF N-MONOFLUOROALKYL TROPANES | GE HEALTHCARE LTD (GB) | 2019-11-20 | — | — | EP | disclosed |
| US-20190117637-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-04-25 | — | — | US | disclosed |
| WO-1995006468-A1 | METHOD FOR TREATING MIGRAINE HEADACHES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-03-09 | — | — | WO | disclosed |
| EP-0314690-A4 | SIGMA BRAIN RECEPTOR LIGANDS AND THEIR USE. | OREGON STATE (US) | 1989-11-07 | — | — | EP | disclosed |
| EP-0314690-A1 | SIGMA BRAIN RECEPTOR LIGANDS AND THEIR USE. | OREGON STATE (US) | 1989-05-10 | — | — | EP | disclosed |
| WO-1988000583-A1 | SIGMA BRAIN RECEPTOR LIGANDS AND THEIR USE | STATE OF OREGON ACTING BY AND THROUGH THE STATE BO (US) | 1988-01-28 | — | — | WO | disclosed |
| US-4105659-A | ANTAGONISTS, ANALGESICS | STERLING DRUG INC. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4071508-A | SIMULTANEOUS POLYMERIZATION | PLASTOMEDICAL SCIENCES, INC. (US) | 1978-01-31 | — | — | US | disclosed |
| US-4036788-A | Anionic hydrogels based on heterocyclic N-vinyl monomers | PLASTOMEDICAL SCIENCES, INC. (US) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019060-A1 | Sigma receptor ligands and their medical uses | TMEM97, SIGMAR1, GPR119 | SIGMAR1 2/4885OPRM1 14/4885OPRD1 63/4885 |
| US-20220009919-A1 | PREPARATION OF N-MONOFLUOROALKYL COMPOUNDS | PFAS, INMT, SLCO4C1 | SIGMAR1 56/4885OPRM1 824/4885OPRD1 868/4885 |
| US-20240197699-A1 | BENZOMORPHAN DERIVATE FOR USE IN THERAPY | FABP4, ADIPOR1, GPR119 | SIGMAR1 298/4885OPRM1 6/4885OPRD1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.